The results underscore the growing financial impact of orphan drugs on Italy's healthcare budget. This analysis offers a quantitative projection of the resources required to ensure continued access to innovative therapies for RDs.
No takes yet. Share an insight, caveat, or question.
Marcellusi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: